ACAD vs PCRX
As of Sep 20, 2026, Acadia Pharmaceuticals (ACAD) scores 6.9/10 and Pacira BioSciences (PCRX) 5.4/10 on AlphaStocks' five-model composite, so ACAD scores higher. PCRX trades 90% above its model fair value.
ACAD
ACADIA PHARMACEUTICALS INC
6.9
Consider Buy
$27.27
PCRX
Pacira BioSciences, Inc.
5.4
Consider Buy
$24.70
ACAD vs PCRX: Which is the Better Investment?
ACADIA PHARMACEUTICALS INC (ACAD) scores 6.9/10 while Pacira BioSciences, Inc. (PCRX) scores 5.4/10 on AlphaStocks' composite model. ACADIA PHARMACEUTICALS INC has the higher composite rating of Consider Buy. On a P/E basis, ACADIA PHARMACEUTICALS INC trades at 11.8x, making it the more attractively priced of the two.
This comparison is algorithmically generated and is not financial advice.
| Metric | ACAD | PCRX |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 6.9/10▲ | 5.4/10 |
| Rating | Consider Buy▲ | Consider Buy |
| Price | $27.27 | $24.70 |
| P/E Ratio | 11.8▲ | 158.2 |
| ROE | 12.9%▲ | 0.7% |
| Market Cap | $5B | $1B |
| Fair Value | — | $13.01 |
| Dividend Yield | — | — |
| Sector Rank | #15 of 168▲ | #81 of 168 |
| Model Verdicts | ||
| Piotroski | Attractive | Strong▲ |
| Buffett | Neutral | Attractive▲ |
| Graham | Neutral | Neutral |
| Lynch | Limited Data | Neutral▲ |
| Greenblatt | Limited Data | Caution▲ |
Related comparisons
ACAD vs PCRX: Which Stock Scores Higher?
ACADIA PHARMACEUTICALS INC (ACAD) and Pacira BioSciences, Inc. (PCRX) are both in the Health Care sector. ACAD currently leads with a composite score of 6.9/10 (Consider Buy) compared to PCRX's 5.4/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer